Nexvet to Present at the Cowen and Company 36th Annual Health Care Conference

DUBLIN, Ireland, Feb. 29, 2016 -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the Cowen and Company 36th Annual Health Care Conference in Boston on Wednesday, March 9 at 10:40AM ET.

Dr. Heffernan will provide an overview of Nexvet’s pioneering developments in the field of biopharmaceuticals for companion animals in the therapeutic areas of pain, inflammation, allergy and immuno-oncology.

A live webcast of the presentation can be accessed by visiting the investor relations section of Nexvet’s website at http://ir.nexvet.com. A replay of the webcast will be available for 30 days following the presentation.

About Nexvet (www.nexvet.com)
Nexvet is a veterinary biologics developer focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet’s proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (“mAbs”) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.

Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, clinical development in the United States and Europe and has acquired biomanufacturing capabilities in Ireland.

Further information:

Investors
Candice Knoll
Blueprint Life Science Group
+1 415-375-3340 Ext. 4
[email protected]

Media
Jessica Burns
Berry & Company Public Relations
+1 212-253-8881
[email protected]